Current perspectives on camptothecins in cancer treatment - Wikidata - awgldk - TriplyDB

Current perspectives on camptothecins in cancer treatment

Current perspectives on camptothecins in cancer treatment

http://www.wikidata.org/entity/Q42715927

about

Topoisomerase I targeting agents in small-cell lung cancer.20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study.Clinical use of topoisomerase I inhibitors in anticancer treatment.What is cancer chemotherapy?Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.Bigelovin triggered apoptosis in colorectal cancer in vitro and in vivo via upregulating death receptor 5 and reactive oxidative species.Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development.Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.Transport and killing mechanism of a novel camptothecin-deoxycholic acid derivate on hepatocellular carcinoma cells.Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro.Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation.Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying.CPT accumulation in the fruit and during early phases of plant development in Camptotheca acuminata Decaisne (Nyssaceae).Topoisomerases as anticancer targets.Interaction of human serum albumin with 10-hydroxycamptothecin: spectroscopic and molecular modeling studies.Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.Clinical pharmacology of camptothecins.

P2860

Q31935315-EE2C4CCC-5510-44E0-95BC-5B28D55A2C9A Q33299859-F59F3FCB-E782-4A95-B670-0248D3476662 Q34056907-D24D218F-32A9-4C57-BAAC-05AEB5AE3247 Q34301165-F528AF8A-861E-4ABE-BB2B-EC4D06C3120E Q36293009-BBAA47C1-2F8D-4CCF-ADCD-7EE092F6BD9D Q37388109-263667D0-3243-46E2-92B8-0E927887562F Q37633880-AF36C90B-3C1F-4083-8484-A397DDB85B97 Q38708186-2C519723-3A9B-4FFC-B25F-EFAAC0977EC4 Q38945299-19277C13-BAFC-4205-95B6-BB6FC3C49F9D Q39005112-35C54AB9-7578-4548-93F8-814E15FDC665 Q39036296-310A686C-4895-4854-BB9A-DD775BD4F43D Q39289157-7B5560F7-80B4-4E9C-B9FD-CAEE42D4BF44 Q40501804-81043B1A-354C-4697-8812-0EDF4E293BF0 Q40562765-F41EA5E2-623A-4DA2-9792-A7D9F79124B3 Q41064018-B7F3EBC7-2D53-408C-BE3F-545C66F6F6D5 Q43007521-1A2210E2-B0AE-4922-9ACA-1A135B179E35 Q43234585-51085004-D750-4EF2-A50E-A58EA4B9DEC6 Q43695525-B26F9E36-8ECB-4406-9FDC-F07880C4A2FD Q46853645-C53F8FC8-448F-4369-92B4-B86E6DD323FE Q49832269-DE2051E7-BD82-421B-8E93-8D0DE6001DD5 Q51476342-6100C500-F8E0-4CFA-9579-A4DE752A45EF Q51891802-44D9C6D3-8A0B-42E1-A3E4-50034E6D5CEF Q53780736-6525C288-2B60-4145-ABCA-633D8869A259

P2860

Current perspectives on camptothecins in cancer treatment

http://www.wikidata.org/entity/Q42715927

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh

1996年學術文章

@zh-hant

name

Current perspectives on camptothecins in cancer treatment

@en

Current perspectives on camptothecins in cancer treatment

@nl

type

label

Current perspectives on camptothecins in cancer treatment

@en

Current perspectives on camptothecins in cancer treatment

@nl

prefLabel

Current perspectives on camptothecins in cancer treatment

@en

Current perspectives on camptothecins in cancer treatment

@nl

P1433

Q42715927-F10EAEDF-FB82-45B2-BE52-D07413E9F179

P1476

Q42715927-E804C975-5CD3-4250-A88D-6C665B275191

P2093

Q42715927-7A66547F-4CA6-49B1-8AB4-B801AA1F2B41

Q42715927-B43C6A45-D690-4D8D-B47D-A2C513FD4D88

P2860

Q42715927-01055A53-1B72-495F-8513-CE59301D40B9

Q42715927-0BB3A03F-306A-413A-87D6-ACB48D9E8B88

Q42715927-142707CE-DF7F-4FD7-BB5A-31D349E55480

Q42715927-2F1AC363-829E-41CA-BA8C-CF0F10E3AF2E

Q42715927-33477FD2-AF18-49D1-AFAD-E6A49A9A3D22

Q42715927-3AF0B4F7-00FE-48B2-A1F5-F1A5FA6D1621

Q42715927-3DA4F0FC-959F-4B55-8994-3AAF5CA0FB6A

Q42715927-3E507BB3-5DC6-497F-9455-43E6A0FB75AA

Q42715927-3F0F8513-302A-45B3-9E65-9B3CC0A0FDEC

Q42715927-3FB3D348-E067-43BD-8C00-D9A40769D194

P2888

Q42715927-0AEE4CA0-4EC7-4088-A5C6-705A455E156C

P304

Q42715927-5E625B44-33C0-4CEA-8242-22B8B603F0B1

P31

Q42715927-07ab431e-c103-413e-88aa-84c4efb3d33d

Q42715927-6EADDE08-7E00-4A04-8D0E-C760396CBB40

Q42715927-A10B288E-F2F4-44C5-A467-2810DF911792

P356

Q42715927-93C192FA-FA37-4C42-A2A1-A1743493F20C

P407

Q42715927-D20C7D4C-DD1A-4597-B286-7084B55441D1

P433

Q42715927-1664224B-B97D-47FE-B459-91CB63C0C05D

P478

Q42715927-6AE56B18-51F4-41DB-A74B-10D2AA394208

P577

Q42715927-6E18C011-FBE0-4B3F-BA1F-368E044D8C5D

P5875

Q42715927-49BF6923-672B-4AC8-B0C2-40CAE3D451D6

P6179

Q42715927-558B5D94-6336-472F-810D-4A89DF7208AD

P698

Q42715927-0CD4F049-4088-4CCA-8D7D-86718F362C00

P921

Q42715927-7292A1B8-9E56-4670-B666-F9D6D91351AC

P932

Q42715927-020B4CDE-2106-40B8-AEB5-462FF44FF6A3

P356

P1433

British Journal of Cancer

P1476

Current perspectives on camptothecins in cancer treatment

@en

P2093

E A Eisenhauer

http://www.w3.org/2001/XMLSchema#string

J Dancey

http://www.w3.org/2001/XMLSchema#string

P2860

Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation.

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.

Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

P2888

P304

327-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1996.362

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

1996-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14507619

http://www.w3.org/2001/XMLSchema#string

P6179

1013699484

http://www.w3.org/2001/XMLSchema#string

P698

8695345

http://www.w3.org/2001/XMLSchema#string

P921

P932

2074644

http://www.w3.org/2001/XMLSchema#string